Download:
pdf |
pdfDEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Centers for Disease Control
and Prevention (CDC)
Memorandum
Date
November 17, 2017
From
Kathy Masterson, CIP
IRB Administrator, NIOSH Institutional Review Board
Subject
IRB Approval of Continuation of NIOSH Protocol 13-HELD-03XP, “Factors Influencing
the Transmission of Influenza” (Expedited)
To
William Lindsley, PhD
Project Officer, HELD, NIOSH
The NIOSH IRB has reviewed and approved your request to continue protocol 13-HELD03XP for the maximum allowable period of one year and it will expire on November 17,
2018. The protocol was reviewed in accordance with the expedited review process outlined
in 45 CFR 46.110(b)(1), Categories (3), (4) and (7).
The IRB determined the study poses minimal risk to subjects.
If other institutions involved in this protocol are being awarded NIOSH funds through the
CDC Procurement and Grants Office (PGO), you are required to send a copy of this IRB
approval to the CDC PGO award specialist handling the award. You are also required to
verify with the award specialist the awardee has provided PGO with the required
documentation and has approval to begin or continue research involving human subjects as
described in this protocol.
As a reminder, the IRB must review and approve all human subjects research protocols at
intervals appropriate to the degree of risk, but not less than once per year. There is no grace
period beyond one year from the last IRB approval date. It is ultimately your responsibility
to submit your research protocol for continuation review and approval by the IRB along
with available IRB approvals from all collaborators. Please keep this approval in your
protocol file as proof of IRB approval and as a reminder of the expiration date. To avoid
lapses in approval of your research and the possible suspension of subject enrollment
and/or termination of the protocol, please submit your continuation request along with
all completed supporting documentation at least six weeks before the protocol's
expiration date of November 17, 2018.
Any problems of a serious nature must be brought to the immediate attention of the
NIOSH IRB, and any proposed changes to the protocol should be submitted as an
amendment to the protocol for NIOSH IRB approval before they are implemented.
If you have any questions, please contact the CDC Human Research Protection Program
(513)533-8591 or e-mail: [email protected].
&HQWHUVIRU'LVHDVH&RQWURODQG3UHYHQWLRQ
QVWLWXWLRQDO HYLHZ RDUG
'DWH5HFHLYHG
E
F
G
F
H
G
I
F
E
J
11/17/2018
$QQLYHUVDU\'DWH BBBBBBBBBB
8VHWKLVVLJQDWXUHSDJHZKHQVXEPLWWLQJ+532IRUPVWR\RXUFHQWHUOHYHO+XPDQ6XEMHFWV
&RQWDFW:KHQVXEPLWWLQJPDWHULDOVZLWKWKHVHIRUPVSOHDVHFRQVHFXWLYHO\QXPEHUDOOSDJHV
EHJLQQLQJZLWKWKHSURWRFROWLWOHSDJHDQGIROORZHGE\FRQVHQWIRUP V DQGDQFLOODU\
GRFXPHQWV6HH
IRUIXUWKHUGHWDLOV
&$1
/HDYHSURWRFRO,'EODQNLIQRW\HWDVVLJQHG
&'&3URWRFRO,'
3URWRFRO7LWOH
Q
R
S
\
]
^
_
`
a
b
c
d
e
f
g
h
d
^
i
d
T
U
j
V
_
k
W
S
h
l
X
a
]
R
Y
d
b
m
i
b
b
i
`
d
`
e
c
i
3ULQFLSDO,QYHVWLJDWRU
3KRQH1XPEHU UHTXLUHG
f
m
f
f
i
I
]
q
y
H
m
[
p
F
]
[
i
L
i
F
o
f
L
y
q
s
d
e
O
RSWLRQDO
P
f
3URWRFRO9HUVLRQ1XPEHU BBBB9HUVLRQ'DWH BBBBBBBBBBBB
g
h
d
n
F
G
F
H
G
I
F
E
J
]
8VHU,'
d
h
t
u
v
k
w
s
b
L
f
i
L
b
L
d
L
r
i
H
r
p
I
N
E
1DPHDQG'HJUHHV
M
[
)LUVW1DPH/DVW1DPH'HJUHHV
o
K
I
L
Z
$PHQGPHQW1XPEHU LIDSSOLFDEOH
3ULPDU\&RQWDFW
3KRQH1XPEHU UHTXLUHG
K
f
h
t
u
v
k
w
x
s
f
x
s
f
J
J
K
y
J
&'&6(9
F
J
K
y
&'&1&'LYLVLRQ
F
r
z
{
|
}
~
w
r
z
{
|
}
~
w
6(9LV&'&¶V6FLHQWLILF(WKLFV9HULILFDWLRQ1XPEHU&'&1&'LYLVLRQLVWKHQDWLRQDOFHQWHURUHTXLYDOHQWDQGGLYLVLRQ
RUHTXLYDOHQWRUFRRUGLQDWLQJFHQWHURURIILFHLIVXEPLWWHGDWWKDWOHYHO
&KHFNDOOWKDWDSSO\LQWKHDSSURSULDWHFROXPQ
!
"
,QLWLDO5HYLHZE\,5%
; ,QLWLDO5HYLHZIRU([HPSWLRQ
&RQWLQXLQJ5HYLHZRI$SSURYHG3URWRFRO
; &RQWLQXLQJ5HYLHZRI([HPSWHG3URWRFRO
5HYLHZRI&KDQJHVWR$SSURYHG3URWRFRO
; 5HYLHZRI&KDQJHVWR([HPSWHG3URWRFRO
,QFLGHQW5HSRUW
6 6XSSOHPHQWDO$GYHUVH(YHQW5HSRUW
(QGRI+XPDQ5HVHDUFK5HYLHZ
(QGRI+XPDQ5HVHDUFK5HYLHZ
&'&¶V5HVHDUFK3DUWQHUV
&'&¶V5HVHDUFK3DUWQHUV
&'&5HO\RQD1RQ&'&,5%
2XWVLGH,QVWLWXWLRQ5HO\RQD&'&,5%
&'&&RYHUDQ,QGLYLGXDO,QYHVWLJDWRU
E
L
r
2
#
$
%
&
(
*
+
(
*
6
'
,
$
*
8
-
9
:
.
;
(
)
/
0
1
9
:
<
2
=
0
;
3
.
4
3
,
4
3
5
(
*
6
4
*
7
>
2
?
1
0
.
0
@
0
A
$
>
B
C
C
C
C
w
F
L
v
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
?
D
5
*
=
$VSULQFLSDOLQYHVWLJDWRU,KHUHE\DFFHSWUHVSRQVLELOLW\IRUFRQGXFWLQJWKLV&'&VSRQVRUHGUHVHDUFKSURMHFWLQDQHWKLFDO
PDQQHUFRQVLVWHQWZLWKWKHSROLFLHVDQGSURFHGXUHVFRQWDLQHGLQ&'&
V
DQGWRDELGHE\WKHSULQFLSOHVRXWOLQHGLQIHGHUDOSROLFLHVIRUWKHSURWHFWLRQRIKXPDQVXEMHFWVDW&)5SDUW
&)5SDUWDQG&)5SDUW
¡
¢
3ULQFLSDO&'&,QYHVWLJDWRU
E
©
ª
©
«
ª
¬
¬
®
²
®
¼
¯
°
½
ª
¾
«
¿
±
À
²
¸
³
¿
´
¾
¸
¯
¾
µ
Á
ª
¾
Â
¼
®
®
ª
½
¶
Á
¼
·
Ã
¸
½
º
¹
¾
ª
Ä
Å
±
³
¾
°
¾
®
²
¯
º
F
¨
¡
G
¨
F
¨
¨
G
¨
I
¡
F
¨
¨
£
E
¨
¤
¨
¨
¥
¦
§
¨
»
Å
$VDVXSHUYLVRURIWKHSULQFLSDOLQYHVWLJDWRU,KHUHE\DFFHSWUHVSRQVLELOLW\IRUHQVXULQJWKDWWKLV&'&VSRQVRUHGUHVHDUFK
SURMHFWLVFRQGXFWHGLQDQHWKLFDOPDQQHUFRQVLVWHQWZLWKWKHSROLFLHVDQGSURFHGXUHVFRQWDLQHGLQ&'&
V
DQGWRDELGHE\WKHSULQFLSOHVRXWOLQHGLQIHGHUDOSROLFLHVIRUWKHSURWHFWLRQRI
KXPDQVXEMHFWVDW&)5SDUW&)5SDUWDQG&)5SDUW
¡
¢
E
¨
Æ
Ç
Æ
È
Ç
Ê
É
É
Ê
Ë
Ï
Ù
Ë
Ì
Í
Ú
Û
Ç
Ü
È
Î
Ý
Ï
Õ
Ð
Ü
Ñ
Û
Õ
Û
Ì
Ò
Þ
Ó
Û
Ô
ß
Ù
Î
à
Æ
à
Ù
Õ
Ü
Ö
á
Ó
×
É
Û
Ç
â
×
Ç
Æ
È
Ç
Ê
É
É
ã
Û
Û
æ
Ê
Ë
Ï
å
é
ç
æ
Ù
Ë
Ì
Í
Ú
Û
Ç
Ü
Î
Ý
Ï
Õ
Ð
Ü
Ñ
Û
Õ
Û
Ì
Ò
Þ
Ó
Û
Ô
ß
Ù
Î
à
Æ
Ü
Ù
Õ
ä
Ö
Ú
Ó
×
É
Û
Ç
â
×
ã
è
ê
î
ê
÷
ë
ì
ø
ù
æ
ú
ç
í
û
î
ó
ï
ú
ù
ð
ó
ë
ù
ñ
ü
ú
é
ò
ý
÷
ê
ø
å
ú
ó
÷
ø
ô
æ
þ
õ
î
ç
ù
î
Û
ý
ÿ
ê
Û
ù
õ
ù
F
¨
¨
¨
¨
¨
¨
G
I
¨
¡
F
¨
£
E
¨
¨
¨
¨
¨
¨
¤
J
¨
¨
¨
¨
¨
¨
¨
¡
¥
¦
§
3,LV7HDP/HDG
F
G
¨
F
¨
G
I
¨
F
¨
E
J
¨
3,LV%UDQFK2IILFLDO
3,LV'LYLVLRQ2IILFLDO
Ø
ã
E
é
¡
G
¨
E
¨
È
F
¨
¨
è
ã
'LYLVLRQ2IILFLDO HJ'LUHFWRURU$'6
å
Ø
%UDQFK2IILFLDO HJ&KLHIRU6HQLRU6FLHQWLVW
Æ
7HDP/HDG
J
¨
¡
ô
F
G
¨
F
¨
G
I
¨
F
¨
E
J
¨
ö
ÿ
,FRQFXUWKDWWKLV&'&VSRQVRUHGUHVHDUFKSURMHFWLVFRQVLVWHQWZLWKWKHSROLFLHVDQGSURFHGXUHVFRQWDLQHGLQ&'&
V
DQGZLWKRWKHUDSSOLFDEOH&'&DQGQDWLRQDOFHQWHUSROLFLHV
¡
¢
&KDLU1,26+,5%
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¡
G
E
J
G
I
¡
F
£
E
¤
J
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
HJ&RQILGHQWLDOLW\2IILFHU&RRUGLQDWLQJ&HQWHU2IILFH2IILFLDO
¨
E
¨
¨
¨
¨
^
¡
`
¥
d
s
g
¦
^
§
_
^
`
d
_
i
d
g
h
b
2WKHU&OHDUDQFH2IILFLDO
¨
E
¨
¨
¨
¨
¨
¨
Approved for IRB Co-Chair,
Gail McConnell, VMD, MPH
BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
¨
7KHSULQFLSDOLQYHVWLJDWRULVUHVSRQVLEOHIRUREWDLQLQJRWKHUUHJXODWRU\UHYLHZVDVQHHGHGZKLFKPD\LQFOXGH20%
FOHDUDQFHXQGHUWKH3DSHUZRUN5HGXFWLRQ$FW 35$ IRUIHGHUDOO\VSRQVRUHGLQIRUPDWLRQFROOHFWLRQV$SSURYDOE\RU
H[HPSWLRQIURPWKH,5%LVXQUHODWHGWR20%FOHDUDQFHUHTXLUHPHQWVXQGHUWKH35$)RUPRUHLQIRUPDWLRQRQZKHWKHU\RXU
VWXG\UHTXLUHVFOHDUDQFHXQGHU35$RURWKHUUHJXODWLRQVSOHDVHFRQVXOWWKHDSSURSULDWHRIILFLDOVZLWKLQ\RXUQDWLRQDOFHQWHU
E
L
r
2
#
$
%
&
(
*
+
(
*
6
'
,
$
*
8
-
9
:
.
;
(
)
/
0
1
9
:
<
2
=
0
;
3
.
4
3
,
4
3
5
(
*
6
4
*
7
>
2
?
1
0
.
0
@
0
A
$
>
B
C
C
C
C
C
w
F
L
v
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
?
D
5
*
:
| File Type | application/pdf |
| File Title | 13-HELD-03XP FORMS 111717 conap Lindsley 2017.pdf |
| Author | kjm3 |
| File Modified | 2017-12-06 |
| File Created | 2017-11-17 |